Good afternoon and welcome to Markets Desk, your midday read on what's moving markets and why.
Apple shares are catching a bid today, and the story behind the move is about risk differentiation. While competitors are pouring capital into AI infrastructure with uncertain returns, Apple's approach is seen as more measured and integrated, giving investors comfort that the downside is contained. That's a meaningful distinction in this environment.
Shifting to biotech, Outlook Therapeutics is having a landmark session after the FDA approved LYTENAVA for wet age-related macular degeneration. This is the first FDA-approved ophthalmic formulation of bevacizumab, and it comes after three prior regulatory setbacks for the company. Approval after that kind of persistence tends to move the needle hard on a small-cap name.
In commodities, wheat is under meaningful pressure heading into the weekend, with Chicago soft red winter contracts down eighteen to twenty cents at midday and Kansas City hard red winter off a similar amount. The catalyst is profit-taking tied to Black Sea developments, with traders unwilling to carry risk through two days of potential headline flow. Cotton is also softer, dragged lower by a crude oil pullback of nearly four dollars per barrel and a weaker dollar index.
That's the tape. Markets Desk, signing off the floor.
